We voiced our thoughts on the increasing need for DMPK influence in discovering new medicines with the publication of Dr Richard Weaver’s article on this subject in the European Biopharmaceutical Review.
We explored why clients use XenoGesis and what makes us different by running our first annual client service questionnaire. This gave us some useful insights into why clients come to XenoGesis and what they think of their experience working together with us on projects. We are able to use this information and feedback to improve the way we do things and the service we provide.
100% of our clients said they would recommend XenoGesis to industry peers or their colleagues – something we are very proud of.
We took this feedback one step further to help us create some new video content with our lovely friends at Seven Video Productions. Video is a powerful means to communicate key messages as well as showcase our facilities and expertise. The corporate video gives a great overview as to who we are and what we do. However, we wanted to go deeper than this and created a second video that focuses on the issues raised in Richard’s article in the EBR. We know and believe that by working with XenoGesis early on, and in a consultative manner, the likelihood of drug discovery project success is increased.
We are proud to say that four of the compounds we have supported have now entered clinical trials. In addition to predicting human PK and efficacious dose ahead of Phase 1, we have modelled single dose clinical PK to predict multiple dose exposure in support of Phase 2 studies.
We continued our overseas growth – this year we experienced our third consecutive year of export growth with one third of our revenue now coming from overseas businesses. We now have clients across six continents and our international client base is set to continue to grow.
We introduced gold standard PBPK modelling and simulation software GastroPlusTM in an expansion of our partnership with Juniper Pharma Services, to bring greater understanding of a compound’s potential exposure in both preclinical and clinical studies.
We addressed topics such as the importance of dose prediction for early drug development in our webinar with Juniper Pharma Services, and the issue of poor solubility in our article from Graham Trevitt.
We were out and about at events far and wide, including: ASMS Thermo Scientific Annual User Meeting, Pharma Integrates, BOS Basel 2017, On Helix, EBF Barcelona, DMG and BOS London 2017, to name a few.
Looking ahead – 2018 is all about growth (again!). Last month’s appointment of new Global Head of Business Development, Dr Rachel Hemsley, is an instrumental step towards the next key phase in our development as the largest independent DMPK CRO in the UK. We have more news to come in the New Year about exciting expansion plans, but for now, the team would like to wish you season’s greetings and all the very best for a prosperous 2018.